Statins for Graves' orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial - The Lancet Diabetes & Endocrinology

Rosuvastatin in the Primary Prevention of Cardiovascular Disease

American Thyroid Association - Our look at the STAGO trial: What's

Role of the mononuclear cell infiltrate in Graves' orbitopathy (GO

The effects of lowering LDL cholesterol with simvastatin plus

PDF) The Role of Oxidative Stress and Therapeutic Potential of

Long-term statins administration exacerbates diabetic nephropathy

PDF) Proof-of-Concept and Randomized, Placebo-Controlled Trials of

Effect of dapagliflozin on the rate of decline in kidney function

PDF) Sirolimus as a second-line treatment for Graves' orbitopathy

High Serum Cholesterol Is a Novel Risk Factor for Graves

Current concepts regarding Graves' orbitopathy - Bartalena - 2022

Recent advances in graves ophthalmopathy medical therapy: a

Proposal for Standardization of Primary and Secondary Outcomes in